In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Lymph nodes, considered the command centers of our immune system, often get swollen and stiff when fighting infection. Now, a UC Berkeley-led team of researchers has discovered that this mechanical ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

An integrin mutation impairs skin T cell migration, enabling HPV proliferation that causes warts and lesions in a rare genetic dermatological condition.